imdusiran (AB-729) / Arbutus 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  vebicorvir (ABI-H0731) / Assembly Biosci
    Trial completion date, Trial termination, Trial primary completion date:  A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) -  Apr 4, 2023   
    P2a,  N=65, Terminated, 
    Available data indicate that adding VBR to AB-729+NrtI does not result in significantly greater on- or post-treatment improvements in markers of active HBV infection vs AB-729+NrtI. Trial completion date: Jan 2024 --> Mar 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Feb 2023; Sponsor decision
  • ||||||||||  imdusiran (AB-729) / Arbutus
    Trial completion date, Trial primary completion date:  Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (clinicaltrials.gov) -  Sep 10, 2022   
    P2,  N=40, Recruiting, 
    Taken together these data suggest that a combination treatment regimen of HBV GalNAc-siRNA and a small molecule PD-L1 inhibitor may provide additional benefit in increasing HBV immune responses, a key driver of CHB functional cure. Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Oct 2023
  • ||||||||||  vebicorvir (ABI-H0731) / Assembly Biosci
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) -  Mar 31, 2022   
    P2a,  N=60, Active, not recruiting, 
    These subjects (and any others from this study who may discontinue NA in the future) will be followed for at least 48 weeks post-NA discontinuation to assess for sustained viral response and evidence of functional cure. Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
  • ||||||||||  AB-729 / Arbutus
    [VIRTUAL] SAFETY AND PHARMACODYNAMICS OF THE GALNAC-siRNA AB-729 IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_83;    
    AB-729 was generally safe and well tolerated following single SC doses, with no clinically relevant ALT/AST changes in the 60mg and 90mg cohorts. Robust mean declines in HBsAg were observed following single doses of 60mg, 90mg and 180mg in CHB subjects that continued through 12 weeks post single dose, supportive of a dosing interval of monthly or less frequently in multiple dose studies.